AstraZeneca
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
This is a modular phase I/IIa, multi-centre, multi-part, open-label, dose escalation, and dose expansion study. Approximately 695 participants will be enrolled and assigned to study treatments. This study consists of individual modules each evaluating safety and tolerability. * Core protocol which contains information applicable to all modules. * Module 1 (AZD9574 monotherapy): This module will include 235 participants: * Part A (dose-escalation cohorts) will include participants with advanced/relapsed ovarian, breast, pancreatic or prostate cancer that are deemed suitable for a Poly ADP-…
Inclusion Criteria: * Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks. * Progressive cancer at the time of enrollment. * Adequate organ and marrow function. Module 1: Part A: \- Participants must have one of the following: (i) Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D (ii) Histologicall…
Participants will receive AZD9574 orally.
Participants will receive temozolomide orally.
Participants will receive \[11C\]AZ1419 3391 intravenously.
Participants will receive T-DXd intravenously.
Participants will receive Dato-DXd intravenously.